Articles By Jack Cush, MD
Biologic Adherence and Drug Survival in RA Patients
A real-world rheumatoid arthritis (RA) cohort study from Israel shows significant variability of drug survival using biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).
Read Article
WSJ: Do Younger or Older Doctors Get Better Results?
A recent Wall St. Journal essay (by AB Jena and C Worsham) suggests that a physician’s effectiveness has less to do with age than with how many patients they see and how well they stay up to date on research.
Read Article
2023 EULAR Recommendations for Imaging in Large Vessel Vasculitis
EULAR has published its expert consensus regarding the recommendations for imaging in the most common types of large vessel vasculitis (LVV) -- giant cell arteritis (GCA) and Takayasu arteritis (TAK).
Read Article
Cardiovascular Disease Precedes ANCA-associated Vasculitis
A nested case–control study from the Danish Nationwide Registries finds an increased risk of cardiovascular (CV) disease in the months preceding diagnosis of ANCA-associated vasculitis (AAV).
Read Article
Manifestations of Systemic Sclerosis Sine Scleroderma
Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%).
Read Article
Mono- and Oligo- are Different (8.18.2023)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Read Article
What Happened to the Pharma Reps?
Dr. Jack Cush weighs in on changes in pharmaceutical "detailing" with suggestions for the future.
Read Article
COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis
The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.
Read Article
Residual Disease in Controlled Axial Spondyloarthritis
Despite being in a state of remission or low disease activity state, in patients with axial spondyloarthritis, up to 42% may still have residual disease.
Read Article
Stable Safety Outcomes with Abatacept
The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns.
Read Article
